EMEA makes safety recommendations for Ritalin use
This article was originally published in Scrip
Executive Summary
The EMEA has made recommendations for safer use of Novartis's Ritalin (methylphenidate) and other methylphenidate-containing medications following concerns over possible cardiovascular and cerebrovascular risks, and psychiatric disorders in children and adolescents.